{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:10:28Z","timestamp":1755799828754},"reference-count":50,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"DOI":"10.7759\/cureus.12419","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T17:49:12Z","timestamp":1609523352000},"source":"Crossref","is-referenced-by-count":10,"title":["Omecamtiv Mecarbil: A Novel Mechanistic and Therapeutic Approach to Chronic Heart Failure Management"],"prefix":"10.7759","author":[{"given":"Pooja H","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rubi","family":"Rodriguez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salim","family":"Surani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George","family":"Udeani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger VL","year":"2013","unstructured":"Roger VL. Epidemiology of heart failure. Circulation Res. 2013, 113:646-659. 10.1161\/CIRCRESAHA.113.300268","journal-title":"Circulation Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/HHF.0b013e318291329a","article-title":"Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association","volume":"6","author":"Heidenreich P","year":"2013","unstructured":"Heidenreich P, Albert N, Allen L, et al.. Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circ Heart Fail. 2013, 6:606-619. 10.1161\/HHF.0b013e318291329a","journal-title":"Circ Heart Fail"},{"key":"ref3","article-title":"Reply: BAG3 protein in advanced-stage heart failure","volume":"2","author":"Storrow AB","year":"2014","unstructured":"Storrow AB, Jenkins CA, Self WH, et al.. Reply: BAG3 protein in advanced-stage heart failure. JACC: Heart Failure. 2014, 2:675.","journal-title":"JACC: Heart Failure"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/0735-1097(93)90455-a","article-title":"The epidemiology of heart failure: the Framingham Study","volume":"22","author":"Ho KK","year":"1993","unstructured":"Ho KK, Pinsky JL, Kannel WB, Levy D. The epidemiology of heart failure: the Framingham Study. J Am Coll Cardiol. 1993, 22:6-13. 10.1016\/0735-1097(93)90455-a","journal-title":"J Am Coll Cardiol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.pcad.2005.02.010","article-title":"Epidemiology of diastolic heart failure","volume":"47","author":"Owan TE","year":"2005","unstructured":"Owan TE, Redfield MM. Epidemiology of diastolic heart failure. Prog Cardiovasc Dis. 2005, 47:320-332. 10.1016\/j.pcad.2005.02.010","journal-title":"Prog Cardiovasc Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.7573\/dic.212518","article-title":"Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil","volume":"7","author":"Kaplinsky E","year":"2018","unstructured":"Kaplinsky E, Mallarkey G. Cardiac myosin activators for heart failure therapy: focus on omecamtiv mecarbil. Drugs Context. 2018, 7:212518. 10.7573\/dic.212518","journal-title":"Drugs Context"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0b013e31829e8776","article-title":"2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines","volume":"128","author":"Yancy CW","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, et al.. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013, 128:240-327. 10.1161\/CIR.0b013e31829e8776","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehw383","article-title":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC","volume":"37","author":"Ponikowski P","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, et al.. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016, 37:2129-2200. 10.1093\/eurheartj\/ehw383","journal-title":"Eur Heart J"},{"key":"ref9","article-title":"The classification of cardiac diagnosis","volume":"77","author":"White P","year":"1921","unstructured":"White P, Myers M. The classification of cardiac diagnosis. JAMA. 1921, 77:1414-1415.","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.17226\/12940","article-title":"Cardiovascular Disability: Updating the Social Security Listings","author":"Institute of Medicine","year":"2010","unstructured":"Institute of Medicine. Cardiovascular Disability: Updating the Social Security Listings. The National Academies Press, Washington, DC; 2010. 10.17226\/12940"},{"key":"ref11","article-title":"Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies","volume":"93","author":"Richardson P","year":"1996","unstructured":"Richardson P. Report of the 1995 World Health Organization\/International Society and Federation of Cardiology Task Force on the definition and classification of cardiomyopathies. Circulation. 1996, 93:841-842.","journal-title":"Circulation"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.12865\/CHSJ.44.03.07","article-title":"Histopathological aspects of the myocardium in dilated cardiomyopathy","volume":"44","author":"Mitrut R","year":"2018","unstructured":"Mitrut R, Stepan AE, Pirici D. Histopathological aspects of the myocardium in dilated cardiomyopathy. Curr Health Sci J. 2018, 44:243-249. 10.12865\/CHSJ.44.03.07","journal-title":"Curr Health Sci J"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.00238","article-title":"Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure","volume":"8","author":"Liu T","year":"2017","unstructured":"Liu T, Song D, Dong J, et. al.. Current understanding of the pathophysiology of myocardial fibrosis and its quantitative assessment in heart failure. Front Physiol. 2017, 8:238-251. 10.3389\/fphys.2017.00238","journal-title":"Front Physiol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.110.942268","article-title":"Molecular pathways underlying cardiac remodeling during pathophysiological stimulation","volume":"122","author":"Kehat I","year":"2010","unstructured":"Kehat I, Molkentin JD. Molecular pathways underlying cardiac remodeling during pathophysiological stimulation. Circulation. 2010, 122:2727-2735. 10.1161\/CIRCULATIONAHA.110.942268","journal-title":"Circulation"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp0909392","article-title":"Systolic heart failure","volume":"362","author":"McMurray JJ","year":"2010","unstructured":"McMurray JJ. Systolic heart failure. N Engl J Med. 2010, 362:228-238. 10.1056\/NEJMcp0909392","journal-title":"N Engl J Med"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.542407","article-title":"Mechanisms and use of calcium-sensitizing agents in the failing heart","volume":"113","author":"Kass DA","year":"2006","unstructured":"Kass DA, Solaro RJ. Mechanisms and use of calcium-sensitizing agents in the failing heart. Circulation. 2006, 113:305-315. 10.1161\/CIRCULATIONAHA.105.542407","journal-title":"Circulation"},{"key":"ref17","article-title":"Cell Biology E-Book","author":"Pollard TD","year":"2017","unstructured":"Pollard TD, Earnshaw WC, Lippincott-Schwartz J, Johnson G. Cell Biology E-Book. Pollard TD, Earnshaw WC, Lippincott-Schwartz J, Johnson G (ed): Elsevier Health Sciences, Philadelphia; 2017."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1021\/ml100138q","article-title":"Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin","volume":"1","author":"Morgan BP","year":"2010","unstructured":"Morgan BP, Muci A, Lu PP, et al.. Discovery of omecamtiv mecarbil the first, selective, small molecule activator of cardiac myosin. ACS Med Chem Lett. 2010, 1:472-477. 10.1021\/ml100138q","journal-title":"ACS Med Chem Lett"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.109.930321","article-title":"Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure","volume":"3","author":"Shen Y-T","year":"2010","unstructured":"Shen Y-T, Malik FI, Zhao X, et al.. Improvement of cardiac function by a cardiac myosin activator in conscious dogs with systolic heart failure. Circulation: Heart Failure. 2010, 3:522-527. 10.1161\/CIRCHEARTFAILURE.109.930321","journal-title":"Circulation: Heart Failure"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-7133.2003.tb00021.x","article-title":"Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography","volume":"9","author":"Yancy C","year":"2003","unstructured":"Yancy C, Abraham WT. Noninvasive hemodynamic monitoring in heart failure: utilization of impedance cardiography. Congestive Heart Failure. 2003, 9:241-250. 10.1111\/j.1751-7133.2003.tb00021.x","journal-title":"Congestive Heart Failure"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.7.883","article-title":"\u03b2-blocker therapy in heart failure: scientific review","volume":"287","author":"Foody JM","year":"2002","unstructured":"Foody JM, Farrell MH, Krumholz HM. \u03b2-blocker therapy in heart failure: scientific review. Jama. 2002, 287:883-889. 10.1001\/jama.287.7.883","journal-title":"Jama"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)04560-8","article-title":"Effect of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial","volume":"357","author":"The CAPRICORN Investigators","year":"2001","unstructured":"The CAPRICORN Investigators. Effect of Carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet. 2001, 357:1385-1390. 10.1016\/s0140-6736(00)04560-8","journal-title":"Lancet"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301","article-title":"Effects of enalapril on mortality in severe congestive heart failure","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. N Engl J Med. 1987, 316:1429-1435. 10.1056\/NEJM198706043162301","journal-title":"N Engl J Med"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni AP","year":"2002","unstructured":"Maggioni AP, Anand I, Gottlieb SO, Latini R, Tognoni G, Cohn JN. Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors. J Am Coll Cardiol. 2002, 40:1414-1421. 10.1016\/S0735-1097(02)02304-5","journal-title":"J Am Coll Cardiol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(97)01187-2","article-title":"Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)","volume":"349","author":"Pitt B","year":"1997","unstructured":"Pitt B, Segal R, Martinez FA, et al.. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). The Lancet. 1997, 349:747-752. 10.1016\/s0140-6736(97)01187-2","journal-title":"The Lancet"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713","article-title":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure","volume":"345","author":"Cohn JN","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001, 345:1667-1675. 10.1056\/NEJMoa010713","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial","volume":"362","author":"Granger CB","year":"2003","unstructured":"Granger CB, McMurray JJ, Yusuf S, et al.. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. The Lancet. 2003, 362:772-776. 10.1016\/S0140-6736(03)14284-5","journal-title":"The Lancet"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(00)02212-1","article-title":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients","volume":"355","author":"Flather MD","year":"2000","unstructured":"Flather MD, Yusuf S, K\u00f8ber L, et al.. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. The Lancet. 2000, 355:1575-1581. 10.1016\/s0140-6736(00)02212-1","journal-title":"The Lancet"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray JJ","year":"2014","unstructured":"McMurray JJ, Packer M, Desai AS, et al.. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014, 371:993-1004. 10.1056\/NEJMoa1409077","journal-title":"N Engl J Med"},{"key":"ref30","article-title":"Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group","volume":"87","author":"Loeb HS","year":"1993","unstructured":"Loeb HS, Johnson G, Henrick A, Smith R, Wilson J, Cremo R, Cohn JN. Effect of enalapril, hydralazine plus isosorbide dinitrate, and prazosin on hospitalization in patients with chronic congestive heart failure. The V-HeFT VA Cooperative Studies Group. Circulation. 1993, 87:78-87.","journal-title":"Circulation"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa042934","article-title":"Combination of isosorbide dinitrate and hydralazine in blacks with heart failure","volume":"351","author":"Taylor AL","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, et al.. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004, 351:2049-2057. 10.1056\/NEJMoa042934","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad F","year":"2011","unstructured":"Zannad F, McMurray JJ, Krum H, et al.. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011, 364:11-21. 10.1056\/NEJMoa1009492","journal-title":"N Engl J Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2005.04.038","article-title":"Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure","volume":"46","author":"Pitt B","year":"2005","unstructured":"Pitt B, White H, Nicolau J, et al.. Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol. 2005, 46:425-431. 10.1016\/j.jacc.2005.04.038","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure","volume":"341","author":"Pitt B","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, et al.. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999, 341:709-717. 10.1056\/NEJM199909023411001","journal-title":"N Engl J Med"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in patients with heart failure and reduced ejection fraction","volume":"381","author":"McMurray JJ","year":"2019","unstructured":"McMurray JJ, Solomon SD, Inzucchi SE, et al.. Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med. 2019, 381:1995-2008. 10.1056\/NEJMoa1911303","journal-title":"N Engl J Med"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.108.821785","article-title":"Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?","volume":"2","author":"Felker GM","year":"2009","unstructured":"Felker GM, O'Connor CM, Braunwald E. Loop diuretics in acute decompensated heart failure: necessary? Evil? A necessary evil?. Circulation: Heart Failure. 2009,  2:56-62. 10.1161\/CIRCHEARTFAILURE.108.821785","journal-title":"Circulation: Heart Failure"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199702203360801","article-title":"The effect of digoxin on mortality and morbidity in patients with heart failure","volume":"336","author":"The Digitalis Investigation Group","year":"1997","unstructured":"The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997, 336:525-533. 10.1056\/NEJM199702203360801","journal-title":"N Engl J Med"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1093\/gerona\/62.3.323","article-title":"Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations","volume":"62","author":"Ahmed A","year":"2007","unstructured":"Ahmed A. Digoxin and reduction in mortality and hospitalization in geriatric heart failure: importance of low doses and low serum concentrations. J Gerontol A Biol Sci Med Sci. 2007, 62:323-329. 10.1093\/gerona\/62.3.323","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi687","article-title":"Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial","volume":"27","author":"Ahmed A","year":"2006","unstructured":"Ahmed A, Rich MW, Love TE, et al.. Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial. Eur Heart J. 2006, 27:178-186. 10.1093\/eurheartj\/ehi687","journal-title":"Eur Heart J"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehi686","article-title":"Rehabilitating digoxin","volume":"27","author":"Brophy JM","year":"2006","unstructured":"Brophy JM. Rehabilitating digoxin. Eur Heart J. 2006, 27:127-129. 10.1093\/eurheartj\/ehi686","journal-title":"Eur Heart J"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study","volume":"376","author":"Swedberg K","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, et al.. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010, 376:875-885. 10.1016\/S0140-6736(10)61198-1","journal-title":"Lancet"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00874","article-title":"If channel as an emerging therapeutic target for cardiovascular diseases: a review of current evidence and controversies","volume":"8","author":"Mengesha HG","year":"2017","unstructured":"Mengesha HG, Tafesse TB, Bule MH. If channel as an emerging therapeutic target for cardiovascular diseases: a review of current evidence and controversies. Front Pharmacol. 2017, 8:874. 10.3389\/fphar.2017.00874","journal-title":"Front Pharmacol"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1001\/jama.287.12.1541","article-title":"Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial","volume":"287","author":"Cuffe MS","year":"2002","unstructured":"Cuffe MS, Califf RM, Adams KF Jr, et al.. Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. Jama. 2002, 287:1541-1547. 10.1001\/jama.287.12.1541","journal-title":"Jama"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2005.08.018","article-title":"How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure?","volume":"150","author":"Williams SG","year":"2005","unstructured":"Williams SG, Jackson M, Cooke GA, et al.. How do different indicators of cardiac pump function impact upon the long-term prognosis of patients with chronic heart failure?. Am Heart J. 2005, 150:1-6. 10.1016\/j.ahj.2005.08.018","journal-title":"Am Heart J"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: a potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik FI","year":"2011","unstructured":"Malik FI, Hartman JJ, Elias KA, et al.. Cardiac myosin activation: a potential therapeutic approach for systolic heart failure. Science. 2011, 331:1439-1443. 10.1126\/science.1200113","journal-title":"Science"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.yjmcc.2009.11.019","article-title":"The molecular basis of the steep force-calcium relation in heart muscle","volume":"48","author":"Sun Y-B","year":"2010","unstructured":"Sun Y-B, Irving M. The molecular basis of the steep force-calcium relation in heart muscle. J Mol Cell Cardiol. 2010, 48:859-865. 10.1016\/j.yjmcc.2009.11.019","journal-title":"J Mol Cell Cardiol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2014.02.011","article-title":"Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases","volume":"106","author":"Spudich JA","year":"2014","unstructured":"Spudich JA. Hypertrophic and dilated cardiomyopathy: four decades of basic research on muscle lead to potential therapeutic approaches to these devastating genetic diseases. Biophys J. 2014, 106:1236-1249. 10.1016\/j.bpj.2014.02.011","journal-title":"Biophys J"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study","volume":"67","author":"Teerlink JR","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJ, et al.. Acute treatment with omecamtiv mecarbil to increase contractility in acute heart failure: the ATOMIC-AHF study. J Am Coll Cardiol. 2016, 67:1444-1455. 10.1016\/j.jacc.2016.01.031","journal-title":"J Am Coll Cardiol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32049-9","article-title":"Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial","volume":"388","author":"Teerlink JR","year":"2016","unstructured":"Teerlink JR, Felker GM, McMurray JJ, et al.. Chronic oral study of myosin activation to increase contractility in heart failure (COSMIC-HF): a phase 2, pharmacokinetic, randomised, placebo-controlled trial. Lancet. 2016, 388:2895-2903. 10.1016\/S0140-6736(16)32049-9","journal-title":"Lancet"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2019.12.001","article-title":"Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF","volume":"8","author":"Teerlink JR","year":"2020","unstructured":"Teerlink JR, Diaz R, Felker GM, et al.. Omecamtiv mecarbil in chronic heart failure with reduced ejection fraction: rationale and design of GALACTIC-HF. JACC: Heart Failure. 2020, 8:329-340. 10.1016\/j.jchf.2019.12.001","journal-title":"JACC: Heart Failure"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/47520-omecamtiv-mecarbil-a-novel-mechanistic-and-therapeutic-approach-to-chronic-heart-failure-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:27:34Z","timestamp":1707506854000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/47520-omecamtiv-mecarbil-a-novel-mechanistic-and-therapeutic-approach-to-chronic-heart-failure-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":50,"URL":"https:\/\/doi.org\/10.7759\/cureus.12419","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1,1]]}}}